| |
Number of patients (n = 201)
|
Percentage (%)
|
|---|
|
Stage
|
|
I
|
38
|
19
|
|
II
|
101
|
50
|
|
III
|
62
|
31
|
|
N stage
|
|
0
|
139
|
69
|
|
1
|
47
|
23
|
|
2
|
15
|
7
|
|
Grade
|
|
Low
|
50
|
25
|
|
Moderate
|
141
|
70
|
|
High
|
10
|
5
|
|
Localization
|
|
Proximal
|
129
|
64
|
|
Distal
|
72
|
36
|
|
Gender
|
|
Female
|
112
|
56
|
|
Male
|
89
|
44
|
|
Age
|
|
< 70
|
60
|
30
|
|
≥ 70
|
141
|
70
|
| |
Number of cancers (n = 197)
|
Percentage (%)
|
|
MSI status
|
|
MSI
|
61
|
31
|
|
MSS
|
136
|
69
|
|
BRAF status
|
|
Mutation
|
52
|
27
|
|
Wild type
|
144
|
73
|
- The MSS group includes both MSS and MSI-low samples. BRAF status is evaluated for the V600E hotspot. For one cancer, BRAF status could not be determined
-
MSI microsattelite instability, MSS microsattelite stable
